Several key-pathways for the aberrant activation of fibroblasts in systemic sclerosis (SSc) have been identified in preclinical studies during the last years. The presentation will summerize recently identified molecular targets for novel anti-fibrotic approaches. We will focus in particular on morphogenic pathways, serotonin receptors and nuclear receptors. We will discuss the role of those pathways for fibroblast activation and potential options to target those pathways for the treatment of SSc and other fibrotic diseases.
Disclosure of Interest J. Distler Shareholder of: 4D Science GmbH, Grant/Research support from: Ergonex, BMS, Bayer Pharma, Celgene, Sanofi-Aventis, Novartis, Array Biopharma, Consultant for: Celgene, Bayer Pharma, Pfizer, JB Therapeutics, Speakers Bureau: Actelion, Pfizer, Bayer Pharma, JB Therapeutics